Results: Metronomic CY was safe and well tolerated, and although lymphopaenia (up to grade 3) was observed in a third of all patients, there were no clinical complications.
Introduction
Despite recent progress in the management of early and localised prostate cancer (PC), a substantial number of patients still develop hormone resistant (HRPC) and metastatic disease that can significantly impact on symptoms, quality of life and longevity 1 . There has been considerable interest in exploiting the immunostimulatory and antiangiogenic potential of drugs previously thought to be beneficial solely in terms of their cytotoxicity 2 . Cyclophosphamide (CY) is a bifunctional alkylating agent which has been used to treat a very large range of malignancies and has also been long associated with immune activation 3 , and more recently with anti-angiogenesis. Low doses of CY can lead to enhanced immune responses against a variety of antigens. In murine models, low dose CY decreases numbers of suppressor or regulatory T cells (T reg) and directly inhibits the suppressive capability of CD4+25+ T reg cells by enhancing apoptosis and decreasing homeostatic proliferation. Higher doses of CY are associated with cytotoxicity and immunosuppression, whereas continuous low dose scheduling may be immunostimulatory and/or antiangiogenic 4 . Metronomic dosing involves the chronic administration of comparatively low doses of CY at close, regular intervals, with no prolonged drug-free interruptions 5 . This approach is not necessarily designed with the intention of substantially increasing cumulative drug-dose over time; as such it minimizes host toxic side effects and the need for supportive care treatment.
Metronomic dosing of agents such as CY or trofosfamide has shown surprisingly potent and durable antitumour effects in a number of models, including transplantable human lymphoma 6 and human prostate carcinoma 7 . 4 In this study we have evaluated the safety and efficacy of continuous low dose oral cyclophophamide in patients with HRPC, both in view of its potential as a cost effective single agent to palliate HRPC but also possibly as a synergistic agent with cancer vaccines or other antiangiogenic agents.
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Materials and methods
Eligibility Criteria
Men with histologically confirmed prostate cancer, who failed optimal first line androgen deprivation therapy with leutenizing hormone releasing hormone (LHRH) agonist drugs, total androgen blockade therapy or orchidectomy were eligible for the trial. Patients were required to have progressive disease as indicated by 2 consecutive rises in Prostate Specific Antigen (PSA), separated by at least four weeks, from a minimum level of 2ng/ml;, WHO performance status of 0-2 and a life expectancy of at least six months. Biochemical trial entry parameters included castrate levels of serum testosterone (<50ng/ml), adequate bone marrow function, as defined by white blood count of more than 3500/mm The primary endpoint of this study was PSA response (50% fall in PSA levels sustained for at least 4 weeks) as defined by PSA working group criteria. Secondary endpoints included proportion of evaluable patients who showed complete or partial objective radiological response to treatment, a fall in absolute PSA or a fall in PSA velocity, duration of any responses and the safety and tolerability of the continuous dosing.
Measurement of serum markers of angiogenesis and enumeration and functional analysis of peripheral blood Treg was completed in a subset of patients. The study was a two stage design using the Gehan principle 8 . Initially 15 patients were recruited, then extended to 50 patients as responses were observed in at least 2 individuals. The study was further extended to 80 patients after discussion with the LREC. 
Efficacy
On an intention to treat basis, the response rate was 34.5% inclusive of objective and PSA (absolute reduction and reduction in PSAV) parameters, table 3. One patient had a partial response by RECIST, and two patients a PSA fall of >50%. The majority of the responders had localised disease, with no clear difference in patients with bone and/or nodal disease. There was no correlation between response and Gleason grading or ethnicity. The majority of the non responders had either locally advanced or bone 10 metastatic disease. The median duration of response was 7.5 months (confidence intervals 3-18 months), the median survival has not yet been reached. The overall survival is shown in figure 1 . The proportion of patients still alive reflects the high proportion with localised disease at recruitment. There was no correlation between survival and Gleason grading or site of metastases. The majority of patients stopped treatment due to rapidly rising PSA, although a significant proportion included grade 3 haematological toxicity (lymphopaenia mainly) or objective progression by radiology, 
Discussion
Despite the reported survival benefit with taxane-based chemotherapy, the prognosis for HRPC patients is still guarded. This study has shown that CY may be administered in a metronomic schedule and is capable of positively altering PSA kinetics without significant toxicity. The median duration of response to metronomic CY was at least that expected with second line hormonal agents but without the toxicity. The advantages of low dose CY were its convenient oral administration, low cost, dosing schedule and lack of toxicity.
The patients enrolled to the study represented a typical cross section of this disease in the clinic-including patients with purely biochemical PSA failure up to those with more advanced and evaluable disease. The majority of patients had localised disease and rising PSA although significant numbers of patients with bone metastases were included.
Our experience with immunological status of patients with nodal (or no) metastases versus bone metastases indicates the presence of bone disease is associated with profound immunosuppression (manuscript submitted). Patients who were unable to continue with the study to the 3 month time point so as to be non-evaluable were characterised by a higher mean PSA, more bone or bone/nodal disease and a slightly higher Gleason grade of 8.
Treatment related toxicity was mild, with no CY-related serious adverse events and no symptoms to suggest haemorrhagic cystitis or second malignancies. Although lymphopaenia was observed in 19 patients, there were no clinical complications.
Myelotoxicity has been reported with this dose of CY previously, and it is also possible that a significant proportion of men had disease metastatic to bone marrow and/or anaemia of chronic disease. 12 Although the number of responders was modest on conventional criteria, there have been a number of studies indicating the utility of PSA kinetics as response criteria. This has included reduction in PSA of less than 50% and reduction in PSA velocity (increased PSA doubling time) 9 . On the other hand, vaccine therapy for prostate cancer has been associated with increased survival without significant alterations in serum PSA 10 . In our recent evaluation of an allogeneic whole cell vaccine for HRPC patients, none of the 28 patients enrolled had objective or conventional PSA responses but a significant proportion had a fall in PSA velocity and an increased time to disease progression compared to other agents used for the same patient group 11 . In terms of the 32 non-responders in this study, there were equal number of patients with bone involved and locally advanced tumours. There was no clear correlation with their histology, ethnicity or previous therapy. It is noteworthy that the main reason to stop treatment in these patients was related to disease progression as noted by an increase in PSA levels, worsening radiological or clinical symptoms and not due to toxicity of the agent.
It is clear from murine and human studies that the biological effect of CY may depend on dose and delivery schedule. Higher doses are associated with cytotoxicity and immunosuppression, whereas continuous low dose scheduling may be immunostimulatory and/or antiangiogenic. Previous studies have reported significant stabilising effects of CY but modest if any response to moderate to high doses of bolus CY, although these studies are from the pre-PSA and pre-CT scan era 12 . Metronomic type dosing of CY has been previously reported as a single agent in one 5 patient study 13 but otherwise has been used in combination with potentially immunosuppressive agents such as steroids and conventional doses of cytotoxic agents in prostate and other cancers. We believe that the observed effects of CY were unlikely to be explained 13 purely by the cytotoxic actions of CY at this dose. Instead, the immunoregulatory and anti-angiogenic effects were probably more likely to explain the data. We assessed the 
